Search clinical trials for: Infigratinib 0.25 mg/kg/day

Total 2143 results

QED Therapeutics, Inc.

Enrolling by invitation

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia (PROPEL3)

Achondroplasia

Australia, United States, Argentina, Canada, France, Germany, Italy, Norway, Singapore, Spain, United Kingdom
QED Therapeutics, Inc.

Recruiting

Study of Infigratinib in Children With Achondroplasia

Achondroplasia

United States, Spain, United Kingdom, France, Canada, Australia
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
ReveraGen BioPharma, Inc.
University of Pittsburgh; Cooperative International Neuromuscular Research...

Completed

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Galeno Desenvolvimento de Pesquisas Clínicas
SocraTec R&D GmbH

Completed

Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days

Menopause

Brazil
University of California, San Francisco
Bill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training... and other collaborators

Completed

Phase2a Primaquine Dose Escalation Study

Malaria

Mali
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
University of Oxford
Mahidol Oxford Tropical Medicine Research Unit; Nangarhar University

Completed

G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria (GAP)

Vivax Malaria

Afghanistan
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

Healthy Volunteers

China
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Yong-Hee Park
Chung-Ang University

Completed

Optimal Dose of Intravenous Oxycodone for Endotracheal Intubation

Blood Pressure | Intubation Complication

Korea, Republic of
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Chimerix

Terminated

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

Protein Losing Enteropathy

United States
Zogenix International Limited, Inc., a subsidiary...

Completed

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

Dravet Syndrome | Lennox Gastaut Syndrome

United States
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Eli Lilly and Company

Completed

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Attention Deficit Hyperactivity Disorder | Oppositional Defiant Disorder

Italy
Georgetown University

Completed

Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging

Peripheral Vascular Disease

United States
Warner Chilcott

Completed

Treatment of Moderate to Severe Facial Acne Vulgaris

Acne Vulgaris

United States
Atox Bio Ltd

Terminated

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Acute Kidney Injury | Peritonitis | Necrotizing Soft Tissue Infection

United States, France
Zogenix International Limited, Inc., a subsidiary...

Active, not recruiting

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome

United States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Spain, Sweden
Shaperon

Recruiting

Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

COVID-19 Pneumonia

Korea, Republic of
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO)

Diabetic Macular Edema (DME)

United States
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
NeuroVive Pharmaceutical AB

Completed

Copenhagen Head Injury Ciclosporin (CHIC) Study (CHIC)

Traumatic Brain Injury

Denmark
Kowa Company, Ltd.

Completed

A Phase III Long Term Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
MacroGenics

Terminated

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)

AML

United States, United Kingdom, Germany, Israel, Spain, France, Italy, Netherlands
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Shahid Beheshti University of Medical Sciences
Isfahan University of Medical Sciences

Completed

Iranian Intensive Care Unit (ICU) Glutamine Study

Trauma Patients in ICU

Iran, Islamic Republic of
University of Oxford
Mahidol University

Completed

Incidence of Vivax Along the Thai Burma Border (VHC)

Vivax Malaria

Thailand
Hansa Biopharma AB
University College London Hospitals

Terminated

IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients

Purpura, Thrombotic Thrombocytopenic

United Kingdom
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Merck Sharp & Dohme LLC

Completed

Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)

Anesthesia
KBP Biosciences
Worldwide Clinical Trials

Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

Hypertension | Chronic Kidney Diseases

United States
Lpath, Inc.

Completed

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Healthy Subjects

United States
Alexion Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-Deficiency

France, United States, United Kingdom, Czechia
Kowa Company, Ltd.

Completed

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

Dyslipidemias

Japan
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
Yale University

Withdrawn

Photodegraded Edible Food Dyes

Thyroid; Functional Disturbance

United States
Regado Biosciences, Inc.

Completed

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD (SC101)

Healthy Volunteer

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KIND-1)

Pruritus | Atopic Dermatitis

United States
Fundacion para la Investigacion Biomedica del Hospital...

Completed

Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis

Cystic Fibrosis

Spain
University of Reading

Completed

An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men

Vasodilation

United Kingdom
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States

Search clinical trials for: Infigratinib 0.25 mg/kg/day

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations